Kim Ely

Dr. Kim Ely


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2018 in Genes
Verified
Journal Article
Open access
PDF file
KEKim Ely
Kim Ely
LBLindsay A. Bischoff
Lindsay A. Bischoff
VWVivian Weiss
Vivian Weiss
The Wnt pathway is essential for stem cell maintenance, but little is known about its role in thyroid hormone signaling and thyroid stem cell survival and maintenance. In addition, the role of Wnt signaling in thyroid cancer progenitor cells is also unclear. Here, we present emerging evidence for the role of Wnt signaling in somatic thyroid stem cell and thyroid cancer stem cell function. An improved understanding of the role of Wnt signaling in thyroid physiology and carcinogenesis is essential for improving both thyroid disease diagnostics and therapeutics.

15 June 2009 in Head & Neck Oncology
Verified
Journal Article
Open access
PDF file
FWFrederick Y Wu
Frederick Y Wu
EYEddy Yang
Eddy Yang
CWChristopher Douglas Willey
Christopher Douglas Willey
KEKim Ely
Kim Ely
GGGaelyn Garrett
Gaelyn Garrett
ACAnthony Joseph Cmelak
Anthony Joseph Cmelak
Nasopharyngeal carcinoma is an uncommon cancer in North America. Its clinical course is typified by locally advanced disease at diagnosis and has a high propensity for both regional and distant spread. It is, therefore, typically treated with a combination of radiation and chemotherapy. This report describes our 10-year clinical and radiological findings in a 48-year-old Vietnamese male patient with locally-advanced T4N1M0 lympho-epithelial carcinoma of the nasopharynx. Despite a long remission period after his initial course of aggressive chemoradiation, his tumor recurred locally after 4 years. Thereafter, throughout a period of over 10 years, he has been treated with multiple courses of re-irradiation and three different trials of chemotherapy. He was ultimately provided with over 30 months of progression-free tumor control with the epidermal growth factor receptor (EGFR)-inhibitor cetuximab. This case illustrates the commonly protracted course of this disease and its responsiveness to multiple treatment modalities.